Teva Pharmaceutical Industries (TEVA) FY2024 results: revenue $16.5 billion, up 4.4% on the year
Teva Pharmaceutical Industries Ltd. (TEVA) reported revenue of $16.5 billion for fiscal 2024, the year ended 31 December 2024, up 4.4% on the year before. Net income was -$1.6 billion, and diluted earnings per share $-1.45. The figures are the company's own, from the 10-K it filed with the SEC on 5 February 2025.
Revenue
$16.5 billion
+4.4% on the year
FY2017FY2024
Operating margin
-1.8%
2.7% a year earlier
FY2017FY2024
Net income
-$1.6 billion
FY2017FY2024
Diluted EPS
-$1.45
FY2017FY2024
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Operating cash flow
1,247
1,368
1,590
-8.8%
Capital expenditure
498
526
548
-5.3%
Free cash flow
749
842
1,042
-11.0%
Free cash flow margin
4.5%
5.3%
7.0%
Cash from investing
792
968
656
-18.2%
Cash from financing
-1,791
-1,913
-1,487
Depreciation and amortisation
1,059
1,153
1,308
-8.2%
Share-based compensation
123
121
124
+1.7%
Diluted shares, weighted
1,131m
1,119m
1,110m
+1.1%
Balance sheet
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Shareholders' equity
5,373
7,506
7,804
-28.4%
Non-controlling interest
7.0
620
794
-98.9%
Redeemable equity
340
0.0
n/a
Debt
17,783
19,833
21,212
-10.3%
Operating lease liabilities
296
320
349
-7.5%
Other liabilities
15,527
15,200
13,847
+2.2%
Total liabilities and equity
39,326
43,479
44,006
-9.6%
Fixed assets
4,581
5,750
5,739
-20.3%
Goodwill
15,147
17,177
17,177
-11.8%
Intangible assets
4,418
5,387
6,270
-18.0%
Cash and equivalents
3,300
3,226
2,801
+2.3%
Receivables
3,059
3,408
3,696
-10.2%
Inventory
3,007
4,021
3,833
-25.2%
Other assets
5,814
4,510
4,490
+28.9%
Total assets
39,326
43,479
44,006
-9.6%
10-K for the year ended 31 December 2024, filed 5 February 2025: the filing.